In the News

MSK Kids is leading a major effort to fully deliver on the promise of precision medicine for our youngest patients.

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

Learn about MSK's new Program for Drug Development in Leukemia (PDD-L), which will offer more clinical trials for many types of leukemia.

MSK molecular geneticist and data scientist Elli Papaemmanuil is leading an initiative to identify the genomic changes that drive pediatric tumors.

Learn about MSK’s expertise in treating vulvar and vaginal cancers, uterine sarcoma, uncommon ovarian cancers, and gestational trophoblastic disease.

Tag along with Jonathan during his most recent visit to MSK Kids. Jonathan was treated for leukemia at MSK Kids starting when he was 9.

A powerful form of MRI could show whether prostate cancer is likely to grow or spread.

Maria Jasin, a member of the Sloan Kettering Institute’s Developmental Biology Program, discusses her research.

Learn some of the ways MSK is advancing care for people with neurofibromatosis.

Pediatric oncologist Julia Glade Bender talks about the challenges of treating rare childhood cancers and how personalized medicine is leading to better therapies for tumors that are especially hard to treat.